Oct 7 (Reuters) – Maat Pharma SA: * MAAT PHARMA ANNOUNCES POSITIVE SECOND SAFETY INTERIM ANALYSIS FROM DSMB FOR PHASE 2B PHOEBUS TRIAL EVALUATING MAAT033 FOR PATIENTS RECEIVING ALLO-HSCT * MAAT PHARMA SA – MAAT033 SHOWS FAVORABLE SAFETY PROFILE AND TOLERABILITY
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Lucy Craymer WELLINGTON, July 13 (Reuters) - Sam Neill, the New Zealand actor best…
By Lucy Craymer WELLINGTON, July 13 (Reuters) - Sam Neill, the New Zealand actor best…
Berlin (dpa) - Overheating is as dangerous for animals as it is for people. If…
July 13 (Reuters) - New Zealand actor Sam Neill died suddenly on Monday at the…
By Lucy Craymer WELLINGTON, July 13 (Reuters) - New Zealand actor Sam Neill died suddenly…
By Lucy Craymer WELLINGTON, July 13 (Reuters) - New Zealand actor Sam Neill died suddenly…